[url="http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/0..."]http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/0...
Harkness to Webcast Tanox Presentation
HOUSTON, Aug. 2 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX)
announced today that Greg Guidroz, Vice President of Finance, and Ashraf
Hanna, Vice President of Strategic Planning, will speak at the Adams Harkness
24th Annual Summer Seminar in Boston, Massachusetts at 11:00 a.m. EDT on
Thursday, August 5, 2004. Dr. Hanna and Mr. Guidroz will provide an overview
of Tanox's business and review corporate objectives for 2004.
A live webcast of the presentation may be accessed on Tanox's corporate
website at [url="http://www.tanox.com"]http://www.tanox.com[/url] . An archived version of the webcast will be
available on the website through September 2, 2004.
About Tanox
Tanox, Inc. is a biopharmaceutical company with demonstrated expertise in
monoclonal antibody technology. The Company is engaged in the discovery and
development of therapeutic monoclonal antibodies designed to address
significant unmet medical needs in the areas of asthma, allergy, inflammation,
diseases affecting the human immune system and infectious diseases. In June
2003, the FDA approved Xolair(R) (omalizumab) For Subcutaneous Use for
treatment of adults and adolescents (12 years of age and above) with moderate-
to-severe persistent asthma who have a positive skin test or in vitro
reactivity to a perennial aeroallergen and whose symptoms are inadequately
controlled with inhaled corticosteroids. Xolair, Tanox's first approved drug,
is an antiimmunoglobulin E, or anti-IgE, antibody that was developed under a
collaboration agreement among Genentech, Inc., Novartis Pharma AG and Tanox.
This release and other information about Tanox, Inc. can be found on the World
Wide Web at [url="http://www.tanox.com"]http://www.tanox.com[/url] .
SOURCE Tanox, Inc.
Web Site: [url="http://www.tanox.com"]http://www.tanox.com[/url]
